Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, Rigamonti A, Barbara C, Grigioni W, Mazziotti A
Istituto di Clinica Medica e Gastroenterologia, University of Bologna, Italy.
Hepatology. 1992 Jul;16(1):132-7. doi: 10.1002/hep.1840160122.
We analyzed the growth pattern of tumor masses and the survival of 39 asymptomatic Italian patients with a total of 59 small (less than or equal to 5 cm in diameter) hepatocellular carcinomas arising from cirrhosis. The total length of the observation period ranged from 90 to 962 days, with an average of 364 +/- 229 (mean +/- S.D.). Doubling time ranged from 27.2 to 605.6 days (mean +/- S.D., 204.2 +/- 135; median = 171.6 days). Three different growth patterns were recognized: (a) tumors with no or very slow initial growth pattern (doubling time greater than 200 days), 10 cases (37%); (b) tumors with declining growth rate over time, 9 cases (33.4%); and (c) tumors with almost constant growth rate, 8 cases (29.6%). Using the stepwise discriminant analysis, we found a score based on albumin, alcohol intake, number of nodules, echo pattern and histological type that allowed a correct prediction of short doubling time (less than or equal to 150 days) in 55.6%, medium doubling time (151 to 300 days) in 60% and long doubling time (greater than 300 days) in 100% of cases. The estimated survival rate of the 39 patients, calculated by the Kaplan-Meier method was 81% at 1 yr, 55.7% at 2 yr and 21% at 3 yr. Stepwise discriminant analysis showed that a score based on sex, HBsAg status, alcohol consumption, ascites, gamma-glutamyltranspeptidase, prothrombin time, Child-Pugh class and all the sonographical parameters could predict 2-yr survival in 100% of cases. We conclude that great variability of growth patterns exists among and within small hepatocellular carcinomas. Prediction of subsequent growth rate is unreliable in most cases.(ABSTRACT TRUNCATED AT 250 WORDS)
我们分析了39例无症状意大利患者肿瘤块的生长模式及生存情况,这些患者共有59个由肝硬化引发的小(直径小于或等于5厘米)肝细胞癌。观察期总时长为90至962天,平均为364±229天(均值±标准差)。倍增时间为27.2至605.6天(均值±标准差,204.2±135;中位数 = 171.6天)。识别出三种不同的生长模式:(a) 初始生长模式无或非常缓慢(倍增时间大于200天)的肿瘤,10例(37%);(b) 随时间生长速率下降的肿瘤,9例(33.4%);(c) 生长速率几乎恒定的肿瘤,8例(29.6%)。通过逐步判别分析,我们发现基于白蛋白、酒精摄入量、结节数量、回声模式和组织学类型的一个评分,可在55.6%的病例中正确预测短倍增时间(小于或等于150天),在60%的病例中正确预测中等倍增时间(151至300天),在100%的病例中正确预测长倍增时间(大于300天)。采用Kaplan-Meier法计算的39例患者的估计生存率在1年时为81%,2年时为55.7%,3年时为21%。逐步判别分析表明,基于性别、乙肝表面抗原状态、酒精消耗、腹水、γ-谷氨酰转肽酶、凝血酶原时间、Child-Pugh分级和所有超声参数的一个评分可在100%的病例中预测2年生存率。我们得出结论,小肝细胞癌之间以及内部存在很大的生长模式变异性。在大多数情况下,预测后续生长速率并不可靠。(摘要截断于250字)